Peter Attia· MD
and these are the same people who bash fibrates who do have two large randomized prospective trials Helsinki and VA head with fibrates and yet they never consider a fibrate they always ho Yool nice since the better drug and at least into the field trial nice or phenol fibrate had all these microvascular there's no prayer nice and reduces diabetic and retinopathy amputations kidney disease but yet there was that battle people bashed fibrates hold them through the high standard of you gotta hit your primary endpoint and ain't never held nice and and to be honest where you're the same that's what Ron Krause didn't that study so I understand what he's talking about there is some dad if you want to extol it but it's not the type of data you and I using so